Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up safety study of ELGN-2112 in children previously treated as preterm infants
NL-OMON61194Phase 4Not yet recruiting
- Sponsor
- Elgan Pharma
- Start
- Feb 2026
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of elgn-gi in intestinal malabsorption (2 arms), sponsored by Elgan Pharma. Primary endpoint: Long-term safety. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
elgn-gi
03
Conditions
intestinal malabsorption
Beyond the preview
Go deeper on NL-OMON61194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61194.